Bloomberg Law
Dec. 1, 2022, 12:28 AM

Lilly Drug Removes Bad Alzheimer’s Protein in Six Months (1)

Robert Langreth
Robert Langreth
Bloomberg News

Eli Lilly & Co. on Wednesday presented promising results on another experimental Alzheimer’s drug -- just a day after rival Eisai Co. reported data on a treatment that looks poised to become the first therapy to unambiguously slow the brain disease.

In a study of 148 early Alzheimer’s patients, Lilly reported that donanemab lowered levels of a bad protein in the brain called amyloid by 65% after six months of treatment. In nearly 38% of the patients, amyloid that had built up for years was fully cleared in that period, according to results presented at the Clinical Trials on Alzheimer’s ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.